Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced that Dr. Ton Logtenberg will step down as CEO, President, Principal Financial Officer and Director of the Company on December 31, 2019.
December 16, 2019
· 7 min read